433 results on '"Benkeser, David"'
Search Results
2. Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs
- Author
-
Jin, Yutong, Luedtke, Alex, Moodie, Zoe, Janes, Holly, and Benkeser, David
- Subjects
Statistics - Methodology - Abstract
Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double-blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time-consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict vaccine efficacy. These responses are termed vaccine correlates of protection. Studies of vaccine-induced immunogenicity vary in size and design, ranging from small, early phase trials, to case-control studies nested in a broader late-phase randomized trial. Moreover, trials can be conducted in geographically diverse study populations across the world. Such diversity presents a challenge for objectively comparing vaccine-induced immunogenicity. To address these practical challenges, we propose a framework that is capable of identifying appropriate causal estimands and estimators, which can be used to provide standardized comparisons of vaccine-induced immunogenicity across trials. We evaluate the performance of the proposed estimands via extensive simulation studies. Our estimators are well-behaved and enjoy robustness properties. The proposed technique is applied to compare vaccine immunogenicity using data from three recent HIV vaccine trials.
- Published
- 2024
3. A Density Ratio Super Learner
- Author
-
Wu, Wencheng and Benkeser, David
- Subjects
Statistics - Machine Learning ,Computer Science - Machine Learning - Abstract
The estimation of the ratio of two density probability functions is of great interest in many statistics fields, including causal inference. In this study, we develop an ensemble estimator of density ratios with a novel loss function based on super learning. We show that this novel loss function is qualified for building super learners. Two simulations corresponding to mediation analysis and longitudinal modified treatment policy in causal inference, where density ratios are nuisance parameters, are conducted to show our density ratio super learner's performance empirically., Comment: 10 pages, 3 figures, 2 tables
- Published
- 2024
4. Fair Risk Minimization under Causal Path-Specific Effect Constraints
- Author
-
Nabi, Razieh and Benkeser, David
- Subjects
Computer Science - Machine Learning ,Statistics - Machine Learning - Abstract
This paper introduces a framework for estimating fair optimal predictions using machine learning where the notion of fairness can be quantified using path-specific causal effects. We use a recently developed approach based on Lagrange multipliers for infinite-dimensional functional estimation to derive closed-form solutions for constrained optimization based on mean squared error and cross-entropy risk criteria. The theoretical forms of the solutions are analyzed in detail and described as nuanced adjustments to the unconstrained minimizer. This analysis highlights important trade-offs between risk minimization and achieving fairnes. The theoretical solutions are also used as the basis for construction of flexible semiparametric estimation strategies for these nuisance components. We describe the robustness properties of our estimators in terms of achieving the optimal constrained risk, as well as in terms of controlling the value of the constraint. We study via simulation the impact of using robust estimators of pathway-specific effects to validate our theory. This work advances the discourse on algorithmic fairness by integrating complex causal considerations into model training, thus providing strategies for implementing fair models in real-world applications.
- Published
- 2024
5. Monte Carlo Integration in Simple and Complex Simulation Designs
- Author
-
Naimi, Ashley I., Benkeser, David, and Rudolph, Jacqueline E.
- Subjects
Statistics - Methodology - Abstract
Simulation studies are used to evaluate and compare the properties of statistical methods in controlled experimental settings. In most cases, performing a simulation study requires knowledge of the true value of the parameter, or estimand, of interest. However, in many simulation designs, the true value of the estimand is difficult to compute analytically. Here, we illustrate the use of Monte Carlo integration to compute true estimand values in simple and complex simulation designs. We provide general pseudocode that can be replicated in any software program of choice to demonstrate key principles in using Monte Carlo integration in two scenarios: a simple three variable simulation where interest lies in the marginally adjusted odds ratio; and a more complex causal mediation analysis where interest lies in the controlled direct effect in the presence of mediator-outcome confounders affected by the exposure. We discuss general strategies that can be used to minimize Monte Carlo error, and to serve as checks on the simulation program to avoid coding errors. R programming code is provided illustrating the application of our pseudocode in these settings., Comment: 10 pages, 2 figures, 2 algorithm boxes
- Published
- 2024
6. Nonparametric Motion Control in Functional Connectivity Studies in Children with Autism Spectrum Disorder
- Author
-
Ran, Jialu, Shultz, Sarah, Risk, Benjamin B., and Benkeser, David
- Subjects
Statistics - Methodology - Abstract
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition associated with difficulties with social interactions, communication, and restricted or repetitive behaviors. To characterize ASD, investigators often use functional connectivity derived from resting-state functional magnetic resonance imaging of the brain. However, participants' head motion during the scanning session can induce motion artifacts. Many studies remove scans with excessive motion, which can lead to drastic reductions in sample size and introduce selection bias. To avoid such exclusions, we propose an estimand inspired by causal inference methods that quantifies the difference in average functional connectivity in autistic and non-ASD children while standardizing motion relative to the low motion distribution in scans that pass motion quality control. We introduce a nonparametric estimator for motion control, called MoCo, that uses all participants and flexibly models the impacts of motion and other relevant features using an ensemble of machine learning methods. We establish large-sample efficiency and multiple robustness of our proposed estimator. The framework is applied to estimate the difference in functional connectivity between 132 autistic and 245 non-ASD children, of which 34 and 126 pass motion quality control. MoCo appears to dramatically reduce motion artifacts relative to no participant removal, while more efficiently utilizing participant data and accounting for possible selection biases relative to the na\"ive approach with participant removal.
- Published
- 2024
7. Technology-Based Interventions, with a Stepped Care Approach, for Reducing Sexual Risk Behaviors and Increasing PrEP Initiation Among Transgender and Gender Expansive Youth and Young Adults
- Author
-
Reback, Cathy J., Cain, Demetria, Rusow, Joshua A., Benkeser, David, Schader, Lindsey, Gwiazdowski, Bevin A., Skeen, Simone J., Hannah, Marissa, Belzer, Marvin, Castillo, Marne, Mayer, Kenneth H., Paul, Mary E., Hill-Rorie, Jonathan, Johnson, Nathan Dorcey, McAvoy-Banerjea, Julie, Sanchez, Travis, Hightow-Weidman, Lisa B., Sullivan, Patrick S., and Horvath, Keith J.
- Published
- 2024
- Full Text
- View/download PDF
8. Prepared, Protected, EmPowered (P3): Primary Results of a Randomized Controlled Trial Using a Social Networking, Gamification, and Coaching App to Promote Pre-exposure Prophylaxis (PrEP) Adherence for Sexual and Gender Minority (SGM) Youth Living in the United States
- Author
-
Hightow-Weidman, Lisa B., Rainer, Crissi, Schader, Lindsey, Rosso, Matthew T., Benkeser, David, Cottrell, Mackenzie, Tompkins, Lauren, Claude, Kristina, Stocks, Jacob B., Yigit, Ibrahim, Budhwani, Henna, and Muessig, Kathryn E.
- Published
- 2024
- Full Text
- View/download PDF
9. Technology-Based Stepped Care to Stem Transgender Adolescent Risk Transmission: Protocol for a Randomized Controlled Trial (TechStep)
- Author
-
Reback, Cathy J, Rusow, Joshua A, Cain, Demetria, Benkeser, David, Arayasirikul, Sean, Hightow-Weidman, Lisa, and Horvath, Keith J
- Subjects
Medicine ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
BackgroundTransgender youth demonstrate significantly higher rates of engagement in sexual risk behaviors relative to their cisgender or gender-conforming counterparts, including high rates of condomless anal intercourse and engagement in sex work. In addition, transgender youth experience increased physical or sexual abuse, victimization, substance use, mental health disorders, incarceration, and homelessness. Owing to these syndemic health disparities, transgender youth are at substantially increased risk of HIV infection. ObjectiveThis protocol aims to describe a randomized controlled trial (RCT), Adolescent Medicine Trials Network 160 TechStep (N=250), which assesses the differential immediate and sustained effects of each of 3 conditions (text messaging, WebApp, or information-only control) for reducing sexual risk behaviors and increasing pre-exposure prophylaxis (PrEP) uptake among high-risk, HIV-negative transgender youth and young adults (aged 15-24 years). MethodsParticipants will be recruited through web-based (targeted social media sites and apps) and offline (print ads and flyers) advertisements, peer and clinic referrals, and street- and venue-based outreach, and by contacting potential participants who have requested contact for future studies. Participants will be randomized into 1 of the 3 conditions: (1) text messaging, (2) WebApp, or (3) information-only control for 6 months. Assessments will occur at baseline and at 3, 6, and 9 months. Participants who do not show improvements in sexual risk or PrEP uptake at the 3-month assessment will be rerandomized to receive weekly electronic coaching (eCoaching) sessions in addition to their assigned text messaging or WebApp intervention, or remain in the original text messaging or WebApp intervention using a 2:1 ratio. Participants originally assigned to the information-only condition are not eligible for rerandomization. ResultsFunding for TechStep was awarded in June 2017. Phase 1 was approved by the Institutional Review Board (IRB) in April 2018. Recruitment began in November 2018 for phase 1, the formative phase. Initial phase 2 IRB approval came in June 2019. The data collection for phase 2, the RCT, is expected to be completed in April 2021. As of March 2020, 54 participants have been enrolled in TechStep. The final results are anticipated in May 2021. ConclusionsBy providing culturally responsive, technology-based interventions, TechStep aims to improve sexual health outcomes among HIV-negative transgender youth and young adults at high risk of HIV. TechStep will evaluate the efficacy of technology-based interventions for reducing HIV sexual risk behaviors and increasing PrEP initiation, adherence, and persistence. The suite of technology-based interventions developed in TechStep, and assessed for efficacy in a 3-condition RCT, represents an important advancement in intervention science toward developing tailored and scalable interventions for transgender youth and young adults. Trial RegistrationClinicalTrials.gov NCT04000724; http://clinicaltrials.gov/ct2/show/NCT04000724 International Registered Report Identifier (IRRID)DERR1-10.2196/18326
- Published
- 2020
- Full Text
- View/download PDF
10. Statistical learning for constrained functional parameters in infinite-dimensional models with applications in fair machine learning
- Author
-
Nabi, Razieh, Hejazi, Nima S., van der Laan, Mark J., and Benkeser, David
- Subjects
Statistics - Machine Learning ,Computer Science - Computers and Society ,Computer Science - Machine Learning ,Statistics - Methodology - Abstract
Constrained learning has become increasingly important, especially in the realm of algorithmic fairness and machine learning. In these settings, predictive models are developed specifically to satisfy pre-defined notions of fairness. Here, we study the general problem of constrained statistical machine learning through a statistical functional lens. We consider learning a function-valued parameter of interest under the constraint that one or several pre-specified real-valued functional parameters equal zero or are otherwise bounded. We characterize the constrained functional parameter as the minimizer of a penalized risk criterion using a Lagrange multiplier formulation. We show that closed-form solutions for the optimal constrained parameter are often available, providing insight into mechanisms that drive fairness in predictive models. Our results also suggest natural estimators of the constrained parameter that can be constructed by combining estimates of unconstrained parameters of the data generating distribution. Thus, our estimation procedure for constructing fair machine learning algorithms can be applied in conjunction with any statistical learning approach and off-the-shelf software. We demonstrate the generality of our method by explicitly considering a number of examples of statistical fairness constraints and implementing the approach using several popular learning approaches.
- Published
- 2024
11. Targeted Machine Learning for Average Causal Effect Estimation Using the Front-Door Functional
- Author
-
Guo, Anna, Benkeser, David, and Nabi, Razieh
- Subjects
Statistics - Methodology ,Statistics - Machine Learning - Abstract
Evaluating the average causal effect (ACE) of a treatment on an outcome often involves overcoming the challenges posed by confounding factors in observational studies. A traditional approach uses the back-door criterion, seeking adjustment sets to block confounding paths between treatment and outcome. However, this method struggles with unmeasured confounders. As an alternative, the front-door criterion offers a solution, even in the presence of unmeasured confounders between treatment and outcome. This method relies on identifying mediators that are not directly affected by these confounders and that completely mediate the treatment's effect. Here, we introduce novel estimation strategies for the front-door criterion based on the targeted minimum loss-based estimation theory. Our estimators work across diverse scenarios, handling binary, continuous, and multivariate mediators. They leverage data-adaptive machine learning algorithms, minimizing assumptions and ensuring key statistical properties like asymptotic linearity, double-robustness, efficiency, and valid estimates within the target parameter space. We establish conditions under which the nuisance functional estimations ensure the root n-consistency of ACE estimators. Our numerical experiments show the favorable finite sample performance of the proposed estimators. We demonstrate the applicability of these estimators to analyze the effect of early stage academic performance on future yearly income using data from the Finnish Social Science Data Archive.
- Published
- 2023
12. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
- Author
-
Magaret, Craig, Li, Li, deCamp, Allan, Rolland, Morgane, Juraska, Michal, Williamson, Brian, Ludwig, James, Molitor, Cindy, Benkeser, David, Luedtke, Alex, Simpkins, Brian, Heng, Fei, Sun, Yanqing, Carpp, Lindsay, Bai, Hongjun, Dearlove, Bethany, Giorgi, Elena, Jongeneelen, Mandy, Brandenburg, Boerries, McCallum, Matthew, Bowen, John, Veesler, David, Sadoff, Jerald, Gray, Glenda, Roels, Sanne, Vandebosch, An, Stieh, Daniel, Le Gars, Mathieu, Vingerhoets, Johan, Grinsztejn, Beatriz, Goepfert, Paul, de Sousa, Leonardo, Silva, Mayara, Casapia, Martin, Losso, Marcelo, Gaur, Aditya, Bekker, Linda-Gail, Garrett, Nigel, Truyers, Carla, Van Dromme, Ilse, Swann, Edith, Marovich, Mary, Follmann, Dean, Neuzil, Kathleen, Corey, Lawrence, Greninger, Alexander, Roychoudhury, Pavitra, Hyrien, Ollivier, Gilbert, Peter, and Little, Susan
- Subjects
Humans ,Ad26COVS1 ,COVID-19 ,SARS-CoV-2 ,Vaccine Efficacy ,Amino Acids ,Antibodies ,Viral ,Antibodies ,Neutralizing - Abstract
In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p
- Published
- 2024
13. Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial
- Author
-
Carpp, Lindsay N., Hyrien, Ollivier, Fong, Youyi, Benkeser, David, Roels, Sanne, Stieh, Daniel J., Van Dromme, Ilse, Van Roey, Griet A., Kenny, Avi, Huang, Ying, Carone, Marco, McDermott, Adrian B., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob C., Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, O’Connell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos J., Luedtke, Alex, Lu, Yiwen, Yu, Chenchen, Juraska, Michal, Hejazi, Nima S., Wolfe, Daniel N., Sadoff, Jerald, Gray, Glenda E., Grinsztejn, Beatriz, Goepfert, Paul A., Bekker, Linda-Gail, Gaur, Aditya H., Veloso, Valdilea G., Randhawa, April K., Andrasik, Michele P., Hendriks, Jenny, Truyers, Carla, Vandebosch, An, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.
- Published
- 2024
- Full Text
- View/download PDF
14. Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services Knowledge-PrEP (A.S.K.-PrEP)
- Author
-
Reback, Cathy J., Landovitz, Raphael J., Benkeser, David, Jalali, Ali, Shoptaw, Steven, Li, Michael J., Mata, Raymond P., Ryan, Danielle, Jeng, Philip J., and Murphy, Sean M.
- Published
- 2024
- Full Text
- View/download PDF
15. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
- Author
-
Zhang, Bo, Fong, Youyi, Fintzi, Jonathan, Chu, Eric, Janes, Holly E., Kenny, Avi, Carone, Marco, Benkeser, David, van der Laan, Lars W. P., Deng, Weiping, Zhou, Honghong, Wang, Xiaowei, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, Chen, Haiyan, Reeder, Isabel, Carpp, Lindsay N., Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Huynh, Chuong, Fichtenbaum, Carl J., Kalams, Spyros, Gay, Cynthia L., Andrasik, Michele P., Kublin, James G., Corey, Lawrence, Neuzil, Kathleen M., Priddy, Frances, Das, Rituparna, Girard, Bethany, El Sahly, Hana M., Baden, Lindsey R., Jones, Thomas, Donis, Ruben O., Koup, Richard A., Gilbert, Peter B., and Follmann, Dean
- Published
- 2024
- Full Text
- View/download PDF
16. Highly adaptive regression trees
- Author
-
Nizam, Sohail and Benkeser, David
- Published
- 2024
- Full Text
- View/download PDF
17. A Huber loss-based super learner with applications to healthcare expenditures
- Author
-
Wu, Ziyue and Benkeser, David
- Subjects
Statistics - Machine Learning ,Computer Science - Machine Learning - Abstract
Complex distributions of the healthcare expenditure pose challenges to statistical modeling via a single model. Super learning, an ensemble method that combines a range of candidate models, is a promising alternative for cost estimation and has shown benefits over a single model. However, standard approaches to super learning may have poor performance in settings where extreme values are present, such as healthcare expenditure data. We propose a super learner based on the Huber loss, a "robust" loss function that combines squared error loss with absolute loss to down-weight the influence of outliers. We derive oracle inequalities that establish bounds on the finite-sample and asymptotic performance of the method. We show that the proposed method can be used both directly to optimize Huber risk, as well as in finite-sample settings where optimizing mean squared error is the ultimate goal. For this latter scenario, we provide two methods for performing a grid search for values of the robustification parameter indexing the Huber loss. Simulations and real data analysis demonstrate appreciable finite-sample gains in cost prediction and causal effect estimation using our proposed method.
- Published
- 2022
18. Efficient estimation of modified treatment policy effects based on the generalized propensity score
- Author
-
Hejazi, Nima S., Benkeser, David, Díaz, Iván, and van der Laan, Mark J.
- Subjects
Statistics - Methodology - Abstract
Continuous treatments have posed a significant challenge for causal inference, both in the formulation and identification of scientifically meaningful effects and in their robust estimation. Traditionally, focus has been placed on techniques applicable to binary or categorical treatments with few levels, allowing for the application of propensity score-based methodology with relative ease. Efforts to accommodate continuous treatments introduced the generalized propensity score, yet estimators of this nuisance parameter commonly utilize parametric regression strategies that sharply limit the robustness and efficiency of inverse probability weighted estimators of causal effect parameters. We formulate and investigate a novel, flexible estimator of the generalized propensity score based on a nonparametric function estimator that provably converges at a suitably fast rate to the target functional so as to facilitate statistical inference. With this estimator, we demonstrate the construction of nonparametric inverse probability weighted estimators of a class of causal effect estimands tailored to continuous treatments. To ensure the asymptotic efficiency of our proposed estimators, we outline several non-restrictive selection procedures for utilizing a sieve estimation framework to undersmooth estimators of the generalized propensity score. We provide the first characterization of such inverse probability weighted estimators achieving the nonparametric efficiency bound in a setting with continuous treatments, demonstrating this in numerical experiments. We further evaluate the higher-order efficiency of our proposed estimators by deriving and numerically examining the second-order remainder of the corresponding efficient influence function in the nonparametric model. Open source software implementing our proposed estimation techniques, the haldensify R package, is briefly discussed.
- Published
- 2022
19. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
- Author
-
Huang, Ying, Hejazi, Nima S, Blette, Bryan, Carpp, Lindsay N, Benkeser, David, Montefiori, David C, McDermott, Adrian B, Fong, Youyi, Janes, Holly E, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R, Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C, O’Connell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, Kenny, Avi, Carone, Marco, Huynh, Chuong, Miller, Jacqueline, Sahly, Hana M El, Baden, Lindsey R, Jackson, Lisa A, Campbell, Thomas B, Clark, Jesse, Andrasik, Michele P, Kublin, James G, Corey, Lawrence, Neuzil, Kathleen M, Pajon, Rolando, Follmann, Dean, Donis, Ruben O, Koup, Richard A, Gilbert, Peter B, Assays, on behalf of the Immune, Moderna, Inc, Efficacy, Coronavirus Vaccine Prevention Network Coronavirus, and Teams, Government CoVPN Biostatistics
- Subjects
Microbiology ,Biological Sciences ,Infectious Diseases ,Biotechnology ,Vaccine Related ,Emerging Infectious Diseases ,Immunization ,Coronaviruses ,Good Health and Well Being ,Humans ,2019-nCoV Vaccine mRNA-1273 ,Antibodies ,Neutralizing ,Antibodies ,Viral ,COVID-19 ,Immunoglobulin G ,Vaccine Efficacy ,binding antibody assay ,immune correlates of protection ,modified treatment policy ,neutralizing antibody assay ,principal stratification ,principal surrogate ,SARS-CoV-2 ,stochastic intervention ,stochastic interventional vaccine efficacy - Abstract
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs.
- Published
- 2023
20. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
- Author
-
Fong, Youyi, McDermott, Adrian, Benkeser, David, Roels, Sanne, Stieh, Daniel, Vandebosch, An, Le Gars, Mathieu, Van Roey, Griet, Houchens, Christopher, Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Amoa-Awua, Obrimpong, Basappa, Manjula, Flach, Britta, Lin, Bob, Moore, Christopher, Naisan, Mursal, Naqvi, Muhammed, Narpala, Sandeep, OConnell, Sarah, Mueller, Allen, Serebryannyy, Leo, Castro, Mike, Wang, Jennifer, Petropoulos, Christos, Luedtke, Alex, Hyrien, Ollivier, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars, Hejazi, Nima, Kenny, Avi, Carone, Marco, Wolfe, Daniel, Sadoff, Jerald, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul, Little, Susan, Paiva de Sousa, Leonardo, Maboa, Rebone, Randhawa, April, Andrasik, Michele, Hendriks, Jenny, Truyers, Carla, Struyf, Frank, Schuitemaker, Hanneke, Douoguih, Macaya, Kublin, James, Corey, Lawrence, Neuzil, Kathleen, Carpp, Lindsay, Follmann, Dean, Gilbert, Peter, Koup, Richard, and Donis, Ruben
- Subjects
Humans ,Ad26COVS1 ,COVID-19 ,ChAdOx1 nCoV-19 ,2019-nCoV Vaccine mRNA-1273 ,Vaccine Efficacy ,Antibodies ,Neutralizing - Abstract
Measuring immune correlates of disease acquisition and protection in the context of a clinical trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing antibody measurements 4 weeks post vaccination as correlates of risk of moderate to severe-critical COVID-19 through 83 d post vaccination in the phase 3, double-blind placebo-controlled phase of ENSEMBLE, an international randomized efficacy trial of a single dose of Ad26.COV2.S. We also evaluated correlates of protection in the trial cohort. Of the three antibody immune markers we measured, we found most support for 50% inhibitory dilution (ID50) neutralizing antibody titre as a correlate of risk and of protection. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; P = 0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43%, 72%) at non-quantifiable ID50 (
- Published
- 2022
21. Individual & joint associations of sexual stigma and mental distress with PrEP uptake, adherence and persistence among US gay and bisexual men
- Author
-
Onwubiko, Udodirim N., Murray, Sarah M., Rao, Amrita, Chamberlain, Allison T., Sanchez, Travis H., Benkeser, David, Holland, David P., Jenness, Samuel M., and Baral, Stefan D.
- Published
- 2024
- Full Text
- View/download PDF
22. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
- Author
-
Allagappen, Jon, Andriesen, Jessica, Ayres, Alison, Baral, Saman, Bekker, Linda-Gail, Besethi, Asiphe, Borremans, Caroline, Braams, Esmee, Brackett, Caroline, Brumskine, William, Chilengi, Roma, Choi, Rachel, Dubula, Thozama, Dumas, Jaiden Seongmi, Dunn, Brooke, Etikala, Radhika, Euler, Zelda, Everett, Sarah, Garrett, Nigel, Gelderblom, Huub, Gill, Katherine, Gillespie, Kevin, Goedhart, Dimitri, Goosmann, Erik, Grant, Shannon, Hands, Ellie, Haynes, Barton, Herringer, Bronwill, Hoosain, Zaheer, Hosseinipour, Mina, Hunidzarira, Portia, Hutter, Julia, Inambao, Mubiana, Innes, Craig, Keyes, Taylor, Kilembe, William, Kotze, Philippus, Kotze, Sheena, Laher, Fatima, Laszlo, Imre, Lazarus, Erica, Liao, Hua-Xin, Lin, Yong, Lu, Helen, Lucas, Judith, Malahleha, Mookho, McNair, Tara, Meerts, Peter, Mgaga, Zinhle, Montlha, Mahlodi, Mosito, Boitumelo, Moultrie, Andrew, Mudrak, Sarah, Oriol-Mathieu, Valérie, Sarzotti-Kelsoe, Marcella, Mathebula, Matson Tso, Matoga, Mitch, McClennen, Rachael, Mda, Pamela, Naicker, Vimla, Naidoo, Logashvari, Okkers, Cindy-Ann, Omarjee, Saleha, Pasmans, Hella, Philip, Tricia, Pinter, Abraham, Pitsi, Annah, Ramos, Ornelia, Randhawa, April, Roels, Sanne, Rohith, Shamiska, Rutten, Lucy, Sadoff, Jerald, Salinas, Gabriela, Salzgeber, Yvonne, Scheppler, Lorenz, Schwedhelm, Katharine, Schuller, Nicolette, Sharak, Angelina, Stanfield-Oakley, Sherry, Sopher, Carrie, Tafatatha, Terence, Takuva, Simbarashe G., Tang, Chan, Vandebosch, An, Viegas, Edna, Voillet, Valentin, Wegmann, Frank, Weijtens, Mo, Wilcox, Stephany, Williams, Anthony, Yu, Chenchen, Yu, Pei-Chun, Yuan, Olive, Zhang, Xuehan, Kenny, Avi, van Duijn, Janine, Dintwe, One, Heptinstall, Jack, Burnham, Randy, Sawant, Sheetal, Zhang, Lu, Mielke, Dieter, Khuzwayo, Sharon, Omar, Faatima Laher, Goodman, Derrick, Fong, Youyi, Benkeser, David, Zou, Rodger, Hural, John, Hyrien, Ollivier, Juraska, Michal, Luedtke, Alex, van der Laan, Lars, Giorgi, Elena E., Magaret, Craig, Carpp, Lindsay N., Pattacini, Laura, van de Kerkhof, Tom, Korber, Bette, Willems, Wouter, Fisher, Leigh H., Schuitemaker, Hanneke, Swann, Edith, Kublin, James G., Pau, Maria G., Buchbinder, Susan, Tomaka, Frank, Nijs, Steven, Lavreys, Ludo, Gelderblom, Huub C., Corey, Lawrence, Mngadi, Kathryn, Gray, Glenda E., Borducchi, Erica, Hendriks, Jenny, Seaton, Kelly E., Zolla-Pazner, Susan, Barouch, Dan H., Ferrari, Guido, De Rosa, Stephen C., McElrath, M Juliana, Andersen-Nissen, Erica, Stieh, Daniel J., Tomaras, Georgia D., and Gilbert, Peter B.
- Published
- 2024
- Full Text
- View/download PDF
23. Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
- Author
-
Juraska, Michal, Early, Angela M, Li, Li, Schaffner, Stephen F, Lievens, Marc, Khorgade, Akanksha, Simpkins, Brian, Hejazi, Nima S, Benkeser, David, Wang, Qi, Mercer, Laina D, Adjei, Samuel, Agbenyega, Tsiri, Anderson, Scott, Ansong, Daniel, Bii, Dennis K, Buabeng, Patrick B Y, English, Sean, Fitzgerald, Nicholas, Grimsby, Jonna, Kariuki, Simon K, Otieno, Kephas, Roman, François, Samuels, Aaron M, Westercamp, Nelli, Ockenhouse, Christian F, Ofori-Anyinam, Opokua, Lee, Cynthia K, MacInnis, Bronwyn L, Wirth, Dyann F, Gilbert, Peter B, and Neafsey, Daniel E
- Published
- 2024
- Full Text
- View/download PDF
24. Inference for natural mediation effects under case-cohort sampling with applications in identifying COVID-19 vaccine correlates of protection
- Author
-
Benkeser, David, Díaz, Iván, and Ran, Jialu
- Subjects
Statistics - Methodology ,Mathematics - Statistics Theory - Abstract
Combating the SARS-CoV2 pandemic will require the fast development of effective preventive vaccines. Regulatory agencies may open accelerated approval pathways for vaccines if an immunological marker can be established as a mediator of a vaccine's protection. A rich source of information for identifying such correlates are large-scale efficacy trials of COVID-19 vaccines, where immune responses are measured subject to a case-cohort sampling design. We propose two approaches to estimation of mediation parameters in the context of case-cohort sampling designs. We establish the theoretical large-sample efficiency of our proposed estimators and evaluate them in a realistic simulation to understand whether they can be employed in the analysis of COVID-19 vaccine efficacy trials., Comment: 26 pages, 6 tables, 2 figures
- Published
- 2021
25. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
- Author
-
Falsey, Ann R, Sobieszczyk, Magdalena E, Hirsch, Ian, Sproule, Stephanie, Robb, Merlin L, Corey, Lawrence, Neuzil, Kathleen M, Hahn, William, Hunt, Julie, Mulligan, Mark J, McEvoy, Charlene, DeJesus, Edwin, Hassman, Michael, Little, Susan J, Pahud, Barbara A, Durbin, Anna, Pickrell, Paul, Daar, Eric S, Bush, Larry, Solis, Joel, Carr, Quito Osuna, Oyedele, Temitope, Buchbinder, Susan, Cowden, Jessica, Vargas, Sergio L, Guerreros Benavides, Alfredo, Call, Robert, Keefer, Michael C, Kirkpatrick, Beth D, Pullman, John, Tong, Tina, Brewinski Isaacs, Margaret, Benkeser, David, Janes, Holly E, Nason, Martha C, Green, Justin A, Kelly, Elizabeth J, Maaske, Jill, Mueller, Nancy, Shoemaker, Kathryn, Takas, Therese, Marshall, Richard P, Pangalos, Menelas N, Villafana, Tonya, and Gonzalez-Lopez, Antonio
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Coronaviruses Vaccines ,Infectious Diseases ,Vaccine Related ,Clinical Research ,Immunization ,Emerging Infectious Diseases ,Coronaviruses ,Prevention ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Neutralizing ,Antibodies ,Viral ,COVID-19 ,ChAdOx1 nCoV-19 ,Chile ,Double-Blind Method ,Female ,Humans ,Immunogenicity ,Vaccine ,Male ,Middle Aged ,Peru ,SARS-CoV-2 ,Spike Glycoprotein ,Coronavirus ,United States ,Vaccine Efficacy ,Young Adult ,AstraZeneca AZD1222 Clinical Study Group ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru.ResultsA total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P
- Published
- 2021
26. Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials
- Author
-
Hejazi, Nima S., van der Laan, Mark J., Janes, Holly E., Gilbert, Peter B., and Benkeser, David C.
- Subjects
Statistics - Methodology - Abstract
The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success, effective vaccines to prevent many high-burden diseases, including HIV, have been slow to develop. Vaccine development can be aided by the identification of immune response markers that serve as effective surrogates for clinically significant infection or disease endpoints. However, measuring immune response marker activity is often costly, which has motivated the usage of two-phase sampling for immune response evaluation in clinical trials of preventive vaccines. In such trials, the measurement of immunological markers is performed on a subset of trial participants, where enrollment in this second phase is potentially contingent on the observed study outcome and other participant-level information. We propose nonparametric methodology for efficiently estimating a counterfactual parameter that quantifies the impact of a given immune response marker on the subsequent probability of infection. Along the way, we fill in theoretical gaps pertaining to the asymptotic behavior of nonparametric efficient estimators in the context of two-phase sampling, including a multiple robustness property enjoyed by our estimators. Techniques for constructing confidence intervals and hypothesis tests are presented, and an open source software implementation of the methodology, the txshift R package, is introduced. We illustrate the proposed techniques using data from a recent preventive HIV vaccine efficacy trial.
- Published
- 2020
- Full Text
- View/download PDF
27. Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
- Author
-
Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
28. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
- Author
-
Fong, Youyi, Huang, Yunda, Benkeser, David, Carpp, Lindsay N., Áñez, Germán, Woo, Wayne, McGarry, Alice, Dunkle, Lisa M., Cho, Iksung, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Hutter, Julia, Keshtkar-Jahromi, Maryam, Beresnev, Tatiana H., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Ake, Julie A., Gay, Cynthia L., Kotloff, Karen L., Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
29. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
- Author
-
Benkeser, David, Fong, Youyi, Janes, Holly E., Kelly, Elizabeth J., Hirsch, Ian, Sproule, Stephanie, Stanley, Ann Marie, Maaske, Jill, Villafana, Tonya, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Ayala, Victor, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Carpp, Lindsay N., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Isaacs, Margaret Brewinski, Makhene, Mamodikoe, Tong, Tina, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Hoffman, Corey, Falsey, Ann R., Sobieszczyk, Magdalena, Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
30. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial
- Author
-
Hejazi, Nima S., Shen, Xiaoying, Carpp, Lindsay N., Benkeser, David, Follmann, Dean, Janes, Holly E., Baden, Lindsey R., El Sahly, Hana M., Deng, Weiping, Zhou, Honghong, Leav, Brett, Montefiori, David C., and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
31. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
- Author
-
Abalos, Karina, Accini, Jose, Aloysia, Naveena, Amuasi, John Humphrey, Ansah, Nana Akosua, Benkeser, David, Berge, Aude, Beyko, Hanna, Bilotkach, Oleksandra, Breuer, Thomas, Bonfanti, Alberto Cadena, Bukusi, Elisabeth, Canter, Richard, Carrillo, Jaime Augusto, Chansinghakul, Danaya, Coux, Florence, Das, Chandan, Das, Santa Kumar, Devlin, Louis, Espinoza, Luis, Fay, Michael, Follmann, Dean, Frago, Carina, Garinga, Agnes, Gilbert, Peter B, Gonzalez, Claudia, Granados, Maria Angelica, Guillery, Lea, Huang, Ying, Hudzina, Kathy, Jain, Manish, Kanodia, Piush, Khandelwal, Nitin, Mutuluuza, Cissy Kityo, Kiweewa, Francis, Kiwanuka, Noah, Kosolsak, Chalit, Kukian, Darshna, Kushwaha, Jitendra Singh, Laot, Thelma, Lopez-Medina, Eduardo, Macareno Arroyo, Hugo, Mandaliya, Kishorchandra, Mamod, Stephanie, Mangarule, Somnath, Martínez, Javier, McClelland, Scott, Menard, Lisa, Mendoza, Sandra, Mohapatra, Satyajit, Moreau, Catherine, Mugo, Nelly, Nduba, Videlis, Noriega, Fernando, Ntege, Patricia Nahirya, Okech, Brenda, Otero, Maria, Ouma, Samuel Gurrion, Oyieko, Janet, Paredes, Mercedes, Pardo, Erwin, Postol, Svitlana, Pekala, David, Peng, Penny, Py, Marie-Laure, Rivas, Enrique, Rivero, Rafael, Rodriguez, Edith, Saleh, Mansoor, Sánchez, Pedro, Sater, Nessryne, Shah, Jinen, Shrestha, Rajeev, Siika, Abraham, Singh, Chandramani, Singh, Veer Bahadur, Tamrakar, Dipesh, Tavares Da-Silva, Fernanda, Otieno Tina, Lucas, Velasquez, Hector, Wabwire, Deo, Wajja, Anne, Zaworski, Elodie, Zhang, Nianxian, Dayan, Gustavo H, Rouphael, Nadine, Walsh, Stephen R, Chen, Aiying, Grunenberg, Nicole, Allen, Mary, Antony, Johannes, Asante, Kwaku Poku, Bhate, Amit Suresh, Beresnev, Tatiana, Bonaparte, Matthew I, Celle, Médéric, Ceregido, Maria Angeles, Corey, Lawrence, Dobrianskyi, Dmytro, Fu, Bo, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Juraska, Michal, Kee, Jia Jin, Kibuuka, Hannah, Koutsoukos, Marguerite, Masotti, Roger, Michael, Nelson L, Neuzil, Kathleen M, Reynales, Humberto, Robb, Merlin L, Villagómez Martínez, Sandra M, Sawe, Fredrick, Schuerman, Lode, Tong, Tina, Treanor, John, Wartel, T Anh, Diazgranados, Carlos A, Chicz, Roman M, Gurunathan, Sanjay, Savarino, Stephen, and Sridhar, Saranya
- Published
- 2023
- Full Text
- View/download PDF
32. Schistosoma mansoni Infection Is Associated With a Higher Probability of Tuberculosis Disease in HIV-Infected Adults in Kenya.
- Author
-
McLaughlin, Taryn A, Nizam, Azhar, Hayara, Felix Odhiambo, Ouma, Gregory Sadat, Campbell, Angela, Khayumbi, Jeremiah, Ongalo, Joshua, Ouma, Samuel Gurrion, Shah, N Sarita, Altman, John D, Kaushal, Deepak, Rengarajan, Jyothi, Ernst, Joel D, Blumberg, Henry M, Waller, Lance A, Gandhi, Neel R, Day, Cheryl L, and Benkeser, David
- Subjects
Rare Diseases ,Clinical Research ,Tuberculosis ,Infectious Diseases ,HIV/AIDS ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Good Health and Well Being ,Adult ,CD4-Positive T-Lymphocytes ,Female ,HIV Infections ,Humans ,Kenya ,Latent Tuberculosis ,Male ,Mycobacterium tuberculosis ,Probability ,Schistosomiasis mansoni ,Young Adult ,HIV ,tuberculosis ,schistosomiasis ,machine learning ,causal inference ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundHelminth infections can modulate immunity to Mycobacterium tuberculosis (Mtb). However, the effect of helminths, including Schistosoma mansoni (SM), on Mtb infection outcomes is less clear. Furthermore, HIV is a known risk factor for tuberculosis (TB) disease and has been implicated in SM pathogenesis. Therefore, it is important to evaluate whether HIV modifies the association between SM and Mtb infection.SettingHIV-infected and HIV-uninfected adults were enrolled in Kisumu County, Kenya, between 2014 and 2017 and categorized into 3 groups based on Mtb infection status: Mtb-uninfected healthy controls, latent TB infection (LTBI), and active TB disease. Participants were subsequently evaluated for infection with SM.MethodsWe used targeted minimum loss estimation and super learning to estimate a covariate-adjusted association between SM and Mtb infection outcomes, defined as the probability of being Mtb-uninfected healthy controls, LTBI, or TB. HIV status was evaluated as an effect modifier of this association.ResultsSM was not associated with differences in baseline demographic or clinical features of participants in this study, nor with additional parasitic infections. Covariate-adjusted analyses indicated that infection with SM was associated with a 4% higher estimated proportion of active TB cases in HIV-uninfected individuals and a 14% higher estimated proportion of active TB cases in HIV-infected individuals. There were no differences in estimated proportions of LTBI cases.ConclusionsWe provide evidence that SM infection is associated with a higher probability of active TB disease, particularly in HIV-infected individuals.
- Published
- 2021
33. Nonparametric inference for interventional effects with multiple mediators
- Author
-
Benkeser, David
- Subjects
Statistics - Methodology ,Mathematics - Statistics Theory ,Statistics - Machine Learning - Abstract
Understanding the pathways whereby an intervention has an effect on an outcome is a common scientific goal. A rich body of literature provides various decompositions of the total intervention effect into pathway specific effects. Interventional direct and indirect effects provide one such decomposition. Existing estimators of these effects are based on parametric models with confidence interval estimation facilitated via the nonparametric bootstrap. We provide theory that allows for more flexible, possibly machine learning-based, estimation techniques to be considered. In particular, we establish weak convergence results that facilitate the construction of closed-form confidence intervals and hypothesis tests. Finally, we demonstrate multiple robustness properties of the proposed estimators. Simulations show that inference based on large-sample theory has adequate small-sample performance. Our work thus provides a means of leveraging modern statistical learning techniques in estimation of interventional mediation effects.
- Published
- 2020
34. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
- Author
-
Abalos, Karina, Adams, Michael, Allaw, Mohamed, Aloysia, Naveena, Amuasi, John Humphrey, Ansah, Nana Akosua, Asante, Kwaku Poku, Benkeser, David, Berge, Aude, Breuer, Thomas, Briesemeister, Liz, Broder, Gail, Bonfanti, Alberto Cadena, Calinescu, Cornell, Canter, Richard, Carrillo, Jaime Augusto, Chansinghakul, Danaya, Coux, Florence, Das, Chandan, Davies, Matthew, Devlin, Louis, Fay, Michael, Follmann, Dean, Frago, Carina, Fukase, Hiroyuki, Garinga, Agnes, Gilbert, Peter B., Gonzalez, Claudia, Granados, Maria Angelica, Greiwe, Cathy, Guillery, Lea, Hall, Jessicalee, Henderson, Jeffrey, Huang, Ying, Hudzina, Kathy, Hural, John, Hutchens, Mark, Jain, Manish, Jennings, William, Kanodia, Piush, Kimmel, Murray, Kirby, William, Khandelwal, Nitin, Kopp, James, Kosolsak, Chalit, Kublin, Jim, Kukian, Darshna, Kushwaha, Jitendra Singh, Laot, Thelma, Lopez-Medina, Eduardo, Arroyo, Hugo Macareno, Mamod, Stephanie, Mangarule, Somnath, Martin, Troy, Menard, Lisa, Mendoza, Sandra, Meyer, Robert, Middleton, Randle, Miracle, Jill, Mizuyama, Kazuyuki, Mohapatra, Satyajit, Moreau, Catherine, Murray, Linda, Nagamatsu, Shinya, Newberg, Joseph, Noriega, Fernando, Nugent, Paul, Peake-Andrasik, Michele, Pekala, David, Peng, Penny, Py, Marie-Laure, Ramirez, Shelly, Reddy, Chinthaparthi Prabhakar, Reynolds, Michelle, Rivas, Enrique, Sater, Nessryne, Shah, Jinen, Sher, Lawrence, Sieger, Silva, Singh, Chandramani, Singh, Veer Bahadur, Sirisuphmitr, Nuchra, Starkey, Thomas, Suzuki, Kazuo, Tamrakar, Dipesh, Tangemen, Cayce, Da-Silva, Fernanda Tavares, Taylor, David, Tharenos, Leslie, Wartel, T. Anh, Zaworski, Elodie, Zhang, Nianxian, Dayan, Gustavo H., Rouphael, Nadine, Walsh, Stephen R., Chen, Aiying, Grunenberg, Nicole, Allen, Mary, Antony, Johannes, Bhate, Amit Suresh, Beresnev, Tatiana, Bonaparte, Matthew I., Celle, Médéric, Ceregido, Maria Angeles, Corey, Lawrence, Fu, Bo, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Juraska, Michal, Kee, Jia Jin, Kaali, Seyram, Koutsoukos, Marguerite, Masotti, Roger, Michael, Nelson L., Neuzil, Kathleen M., Reynales, Humberto, Robb, Merlin L., Uchiyama, Akiyoshi, Sawe, Fredrick, Schuerman, Lode, Shrestha, Rajeev, Tong, Tina, Treanor, John, Diazgranados, Carlos A., Chicz, Roman M., Gurunathan, Sanjay, Savarino, Stephen, and Sridhar, Saranya
- Published
- 2023
- Full Text
- View/download PDF
35. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation
- Author
-
Jin, Yutong, Benkeser, David, Kipiani, Maia, Maranchick, Nicole F., Mikiashvili, Lali, Barbakadze, Ketevan, Avaliani, Zaza, Alghamdi, Wael A., Alshaer, Mohammad H., Peloquin, Charles A., Blumberg, Henry M, and Kempker, Russell R.
- Published
- 2023
- Full Text
- View/download PDF
36. Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
- Author
-
Williamson, Brian D., Magaret, Craig A., Karuna, Shelly, Carpp, Lindsay N., Gelderblom, Huub C., Huang, Yunda, Benkeser, David, and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
37. Efficient Estimation of Pathwise Differentiable Target Parameters with the Undersmoothed Highly Adaptive Lasso
- Author
-
van der Laan, Mark J., Benkeser, David, and Cai, Weixin
- Subjects
Mathematics - Statistics Theory ,Statistics - Methodology - Abstract
We consider estimation of a functional parameter of a realistically modeled data distribution based on observing independent and identically distributed observations. We define an $m$-th order Spline Highly Adaptive Lasso Minimum Loss Estimator (Spline HAL-MLE) of a functional parameter that is defined by minimizing the empirical risk function over an $m$-th order smoothness class of functions. We show that this $m$-th order smoothness class consists of all functions that can be represented as an infinitesimal linear combination of tensor products of $\leq m$-th order spline-basis functions, and involves assuming $m$-derivatives in each coordinate. By selecting $m$ with cross-validation we obtain a Spline-HAL-MLE that is able to adapt to the underlying unknown smoothness of the true function, while guaranteeing a rate of convergence faster than $n^{-1/4}$, as long as the true function is cadlag (right-continuous with left-hand limits) and has finite sectional variation norm. The $m=0$-smoothness class consists of all cadlag functions with finite sectional variation norm and corresponds with the original HAL-MLE defined in van der Laan (2015). In this article we establish that this Spline-HAL-MLE yields an asymptotically efficient estimator of any smooth feature of the functional parameter under an easily verifiable global undersmoothing condition. A sufficient condition for the latter condition is that the minimum of the empirical mean of the selected basis functions is smaller than a constant times $n^{-1/2}$, which is not parameter specific and enforces the selection of the $L_1$-norm in the lasso to be large enough to include sparsely supported basis. We demonstrate our general result for the $m=0$-HAL-MLE of the average treatment effect and of the integral of the square of the data density. We also present simulations for these two examples confirming the theory.
- Published
- 2019
38. Design and analysis considerations for a sequentially randomized HIV prevention trial
- Author
-
Benkeser, David, Horvath, Keith, Reback, Cathy, Rusow, Joshua, and Hudgens, Michael
- Subjects
Statistics - Applications - Abstract
TechStep is a randomized trial of a mobile health interventions targeted towards transgender adolescents. The interventions include a short message system, a mobile-optimized web application, and electronic counseling. The primary outcomes are self-reported sexual risk behaviors and uptake of HIV preventing medication. In order that we may evaluate the efficacy of several different combinations of interventions, the trial has a sequentially randomized design. We use a causal framework to formalize the estimands of the primary and key secondary analyses of the TechStep trial data. Targeted minimum loss-based estimators of these quantities are described and studied in simulation.
- Published
- 2019
- Full Text
- View/download PDF
39. Improved Small-Sample Estimation of Nonlinear Cross-Validated Prediction Metrics
- Author
-
Benkeser, David, Petersen, Maya, and van der Laan, Mark J
- Subjects
Health and social care services research ,8.4 Research design and methodologies (health services) ,Area under the receiver operating characteristic curve ,Cross-validation ,Estimating equation ,Machine learning ,Prediction ,Targeted minimum loss-based estimation ,AUC ,cross-validation ,estimating equations ,machine learning ,prediction ,targeted minimum loss-based estimation ,Statistics ,Econometrics ,Demography ,Statistics & Probability - Abstract
When predicting an outcome is the scientific goal, one must decide on a metric by which to evaluate the quality of predictions. We consider the problem of measuring the performance of a prediction algorithm with the same data that were used to train the algorithm. Typical approaches involve bootstrapping or cross-validation. However, we demonstrate that bootstrap-based approaches often fail and standard cross-validation estimators may perform poorly. We provide a general study of cross-validation-based estimators that highlights the source of this poor performance, and propose an alternative framework for estimation using techniques from the efficiency theory literature. We provide a theorem establishing the weak convergence of our estimators. The general theorem is applied in detail to two specific examples and we discuss possible extensions to other parameters of interest. For the two explicit examples that we consider, our estimators demonstrate remarkable finite-sample improvements over standard approaches.
- Published
- 2020
40. A machine learning-based approach for estimating and testing associations with multivariate outcomes.
- Author
-
Benkeser, David, Mertens, Andrew, Colford, John M, Hubbard, Alan, Arnold, Benjamin F, Stein, Aryeh, and van der Laan, Mark J
- Subjects
canonical correlation ,epidemiology ,machine learning ,multivariate outcomes ,variable importance ,Statistics & Probability ,Statistics - Abstract
We propose a method for summarizing the strength of association between a set of variables and a multivariate outcome. Classical summary measures are appropriate when linear relationships exist between covariates and outcomes, while our approach provides an alternative that is useful in situations where complex relationships may be present. We utilize machine learning to detect nonlinear relationships and covariate interactions and propose a measure of association that captures these relationships. A hypothesis test about the proposed associative measure can be used to test the strong null hypothesis of no association between a set of variables and a multivariate outcome. Simulations demonstrate that this hypothesis test has greater power than existing methods against alternatives where covariates have nonlinear relationships with outcomes. We additionally propose measures of variable importance for groups of variables, which summarize each groups' association with the outcome. We demonstrate our methodology using data from a birth cohort study on childhood health and nutrition in the Philippines.
- Published
- 2020
41. A two-stage super learner for healthcare expenditures
- Author
-
Wu, Ziyue, Berkowitz, Seth A., Heagerty, Patrick J., and Benkeser, David
- Published
- 2022
- Full Text
- View/download PDF
42. A nonparametric super-efficient estimator of the average treatment effect
- Author
-
Benkeser, David, Cai, Weixin, and van der Laan, Mark J
- Subjects
Statistics - Methodology - Abstract
Doubly robust estimators of causal effects are a popular means of estimating causal effects. Such estimators combine an estimate of the conditional mean of the outcome given treatment and confounders (the so-called outcome regression) with an estimate of the conditional probability of treatment given confounders (the propensity score) to generate an estimate of the effect of interest. In addition to enjoying the double-robustness property, these estimators have additional benefits. First, flexible regression tools, such as those developed in the field of machine learning, can be utilized to estimate the relevant regressions, while the estimators of the treatment effects retain desirable statistical properties. Furthermore, these estimators are often statistically efficient, achieving the lower bound on the variance of regular, asymptotically linear estimators. However, in spite of their asymptotic optimality, in problems where causal estimands are weakly identifiable, these estimators may behave erratically. We propose two new estimation techniques for use in these challenging settings. Our estimators build on two existing frameworks for efficient estimation: targeted minimum loss estimation and one-step estimation. However, rather than using an estimate of the propensity score in their construction, we instead opt for an alternative regression quantity when building our estimators: the conditional probability of treatment given the conditional mean outcome. We discuss the theoretical implications and demonstrate the estimators' performance in simulated and real data.
- Published
- 2019
43. Robust inference on the average treatment effect using the outcome highly adaptive lasso
- Author
-
Ju, Cheng, Benkeser, David, and van der Laan, Mark J.
- Subjects
Statistics - Methodology ,Statistics - Computation ,Statistics - Machine Learning - Abstract
Many estimators of the average effect of a treatment on an outcome require estimation of the propensity score, the outcome regression, or both. It is often beneficial to utilize flexible techniques such as semiparametric regression or machine learning to estimate these quantities. However, optimal estimation of these regressions does not necessarily lead to optimal estimation of the average treatment effect, particularly in settings with strong instrumental variables. A recent proposal addressed these issues via the outcome-adaptive lasso, a penalized regression technique for estimating the propensity score that seeks to minimize the impact of instrumental variables on treatment effect estimators. However, a notable limitation of this approach is that its application is restricted to parametric models. We propose a more flexible alternative that we call the outcome highly adaptive lasso. We discuss large sample theory for this estimator and propose closed form confidence intervals based on the proposed estimator. We show via simulation that our method offers benefits over several popular approaches., Comment: The first two authors contributed equally to this work
- Published
- 2018
44. A machine learning-based approach for estimating and testing associations with multivariate outcomes
- Author
-
Benkeser, David, Mertens, Andrew, Arnold, Benjamin F., Colford Jr., John M., Hubbard, Alan, Stein, Aryeh, Jumbe, N. Lntshotshole, and van der Laan, Mark
- Subjects
Statistics - Methodology - Abstract
We propose a method for summarizing the strength of association between a set of variables and a multivariate outcome. Classical summary measures are appropriate when linear relationships exist between covariates and outcomes, while our approach provides an alternative that is useful in situations where complex relationships may be present. We utilize ensemble machine learning to detect nonlinear relationships and covariate interactions and propose a measure of association that captures these relationships. A hypothesis test about the proposed associative measure can be used to test the strong null hypothesis of no association between a set of variables and a multivariate outcome. Simulations demonstrate that this hypothesis test has greater power than existing methods against alternatives where covariates have nonlinear relationships with outcomes. We additionally propose measures of variable importance for groups of variables, which summarize each groups' association with the outcome. We demonstrate our methodology using data from a birth cohort study on childhood health and nutrition in the Philippines.
- Published
- 2018
45. Accounting for motion in resting-state fMRI: What part of the spectrum are we characterizing in autism spectrum disorder?
- Author
-
Nebel, Mary Beth, Lidstone, Daniel E., Wang, Liwei, Benkeser, David, Mostofsky, Stewart H., and Risk, Benjamin B.
- Published
- 2022
- Full Text
- View/download PDF
46. Don't Let Your Analysis Go to Seed: On the Impact of Random Seed on Machine Learning-based Causal Inference.
- Author
-
Schader, Lindsey, Weishan Song, Kempker, Russell, and Benkeser, David
- Abstract
Machine learning techniques for causal effect estimation can enhance the reliability of epidemiologic analyses, reducing their dependence on correct model specifications. However, the stochastic nature of many machine learning algorithms implies that the results derived from such approaches may be influenced by the random seed that is set before model fitting. In this work, we highlight the substantial influence of random seeds on a popular approach for machine learning-based causal effect estimation, namely doubly robust estimators. We illustrate that varying seeds can yield divergent scientific interpretations of doubly robust estimates produced from the same dataset. We propose techniques for stabilizing results across random seeds and, through an extensive simulation study, demonstrate that these techniques effectively neutralize seed-related variability without compromising the statistical efficiency of the estimators. Based on these findings, we offer practical guidelines to minimize the influence of random seeds in real-world applications, and we encourage researchers to explore the variability due to random seeds when implementing any method that involves random steps. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort
- Author
-
Kaiser, Paulina, Arnold, Alice M, Benkeser, David, Hazzouri, Adina Zeki Al, Hirsch, Calvin H, Psaty, Bruce M, and Odden, Michelle C
- Subjects
Clinical Trials and Supportive Activities ,Heart Disease ,Heart Disease - Coronary Heart Disease ,Clinical Research ,Cardiovascular ,Comparative Effectiveness Research ,Health and social care services research ,8.4 Research design and methodologies (health services) ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Bias ,Female ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Longitudinal Studies ,Male ,Models ,Statistical ,Myocardial Infarction ,Observational Studies as Topic ,Propensity Score ,Randomized Controlled Trials as Topic ,Risk Assessment ,observational studies ,statins ,Statistics ,Public Health and Health Services ,Epidemiology - Abstract
BackgroundThe theoretical conditions under which causal estimates can be derived from observational data are challenging to achieve in the real world. Applied examples can help elucidate the practical limitations of methods to estimate randomized-controlled trial effects from observational data.MethodsWe used six methods with varying design and analytic features to compare the 5-year risk of incident myocardial infarction among statin users and non-users, and used non-cardiovascular mortality as a negative control outcome. Design features included restriction to a statin-eligible population and new users only; analytic features included multivariable adjustment and propensity score matching.ResultsWe used data from 5294 participants in the Cardiovascular Health Study from 1989 to 2004. For non-cardiovascular mortality, most methods produced protective estimates with confidence intervals that crossed the null. The hazard ratio (HR) was 0.92, 95% confidence interval: 0.58, 1.46 using propensity score matching among eligible new users. For myocardial infarction, all estimates were strongly protective; the propensity score-matched analysis among eligible new users resulted in a HR of 0.55 (0.29, 1.05)-a much stronger association than observed in randomized controlled trials.ConclusionsIn designs that compare active treatment with non-treated participants to evaluate effectiveness, methods to address bias in observational data may be limited in real-world settings by residual bias.
- Published
- 2018
48. Rejoinder : A Nonparametric Superefficient Estimator of the Average Treatment Effect
- Author
-
Benkeser, David, Cai, Weixin, and van der Laan, Mark J.
- Published
- 2020
49. A Nonparametric Super-Efficient Estimator of the Average Treatment Effect
- Author
-
Benkeser, David, Cai, Weixin, and van der Laan, Mark J.
- Published
- 2020
50. Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020
- Author
-
Baliashvili, Davit, Blumberg, Henry M., Gandhi, Neel R., Averhoff, Francisco, Benkeser, David, Shadaker, Shaun, Gvinjilia, Lia, Turdziladze, Aleksandre, Tukvadze, Nestani, Chincharauli, Mamuka, Butsashvili, Maia, Sharvadze, Lali, Tsertsvadze, Tengiz, Zarkua, Jaba, and Kempker, Russell R.
- Subjects
Infection control -- Methods ,Viral antibodies -- Testing ,Antibodies -- Testing ,Hepatitis C -- Diagnosis -- Care and treatment ,Biological sciences - Abstract
Background The Eastern European country of Georgia initiated a nationwide hepatitis C virus (HCV) elimination program in 2015 to address a high burden of infection. Screening for HCV infection through antibody testing was integrated into multiple existing programs, including the National Tuberculosis Program (NTP). We sought to compare the hepatitis C care cascade among patients with and without tuberculosis (TB) diagnosis in Georgia between 2015 and 2019 and to identify factors associated with loss to follow-up (LTFU) in hepatitis C care among patients with TB. Methods and findings Using national ID numbers, we merged databases of the HCV elimination program, NTP, and national death registry from January 1, 2015 to September 30, 2020. The study population included 11,985 adults (aged [greater than or equal to]18 years) diagnosed with active TB from January 1, 2015 through December 31, 2019, and 1,849,820 adults tested for HCV antibodies between January 1, 2015 and September 30, 2020, who were not diagnosed with TB during that time. We estimated the proportion of patients with and without TB who were LTFU at each step of the HCV care cascade and explored temporal changes. Among 11,985 patients with active TB, 9,065 (76%) patients without prior hepatitis C treatment were tested for HCV antibodies, of which 1,665 (18%) had a positive result; LTFU from hepatitis C care was common, with 316 of 1,557 (20%) patients with a positive antibody test not undergoing viremia testing and 443 of 1,025 (43%) patients with viremia not starting treatment for hepatitis C. Overall, among persons with confirmed viremic HCV infection, due to LTFU at various stages of the care cascade only 28% of patients with TB had a documented cure from HCV infection, compared to 55% among patients without TB. LTFU after positive antibody testing substantially decreased in the last 3 years, from 32% among patients diagnosed with TB in 2017 to 12% among those diagnosed in 2019. After a positive HCV antibody test, patients without TB had viremia testing sooner than patients with TB (hazards ratio [HR] = 1.46, 95% confidence intervals [CI] [1.39, 1.54], p < 0.001). After a positive viremia test, patients without TB started hepatitis C treatment sooner than patients with TB (HR = 2.05, 95% CI [1.87, 2.25], p < 0.001). In the risk factor analysis adjusted for age, sex, and case definition (new versus previously treated), multidrug-resistant (MDR) TB was associated with an increased risk of LTFU after a positive HCV antibody test (adjusted risk ratio [aRR] = 1.41, 95% CI [1.12, 1.76], p = 0.003). The main limitation of this study was that due to the reliance on existing electronic databases, we were unable to account for the impact of all confounding factors in some of the analyses. Conclusions LTFU from hepatitis C care after a positive antibody or viremia test was high and more common among patients with TB than in those without TB. Better integration of TB and hepatitis C care systems can potentially reduce LTFU and improve patient outcomes both in Georgia and other countries that are initiating or scaling up their nationwide hepatitis C control efforts and striving to provide personalized TB treatment., Author(s): Davit Baliashvili 1,*, Henry M. Blumberg 1,2,3, Neel R. Gandhi 1,2,3, Francisco Averhoff 4, David Benkeser 5, Shaun Shadaker 6, Lia Gvinjilia 7, Aleksandre Turdziladze 8, Nestani Tukvadze 9, [...]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.